

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **February 14, 2024**

**Greenwich LifeSciences, Inc.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-39555**  
(Commission  
File Number)

**20-5473709**  
(I. R. S. Employer  
Identification No.)

**3992 Bluebonnet Dr, Building 14**  
**Stafford, TX 77477**  
(Address of principal executive offices, including ZIP code)

**(832) 819-3232**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, \$0.001 par value	GLSI	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 4.01 Changes in Registrant's Certifying Accountant.**

On February 14, 2024, the audit committee of the Board of Directors of Greenwich LifeSciences, Inc. (the "Company") approved the dismissal of MaloneBailey LLP ("Malone") as the Company's independent registered public accounting firm and approved the engagement of RBSM LLP ("RBSM") as the Company's independent registered public accounting firm to audit the Company's consolidated financial statements for the year ended December 31, 2023. Accordingly, on February 15, 2024, Malone was informed that it would be dismissed as the Company's independent registered public accounting firm, effective immediately.

The report of Malone on the Company's financial statements as of December 31, 2022 and 2021, and the related statements of operations, changes in stockholders' equity and cash flows for the years ended December 31, 2021 and 2022 did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles.

During the fiscal years ended December 31, 2022 and 2021 there have been no "reportable events" (as defined in Item 304(a)(1)(v) of Regulation S-K), except for the material weaknesses in the Company's internal control over financial reporting described in Part II, Item 9A, "Controls and Procedures," in the Company's annual reports on Form 10-K for the years ended December 31, 2022 and 2021, respectively and in Part I, Item 4, "Controls and Procedures," in the Company's quarterly reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023 filed with the SEC on May 22, 2023, August 21, 2023 and October 19, 2023, respectively. The Audit Committee has discussed the material weaknesses in the Company's internal control over financial reporting with Malone and has authorized Malone to respond fully to the inquiries of RBSM, the Company's new independent registered public accountants, concerning such weakness.

During the years ended December 31, 2023 and 2022 and through February 14, 2024, there were no disagreements between the Company and Malone on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Malone, would have caused it to make reference to the subject matter of the disagreement in connection with its report covering such period.

During the years ended December 31, 2023 and 2022 and through February 14, 2024, the date the audit committee of the Board approved the engagement of RBSM as the Company's independent registered public accounting firm, neither the Company nor anyone on the Company's behalf consulted with RBSM regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements, and no written report or oral advice was provided to the Company by the Company that the Company concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement, as that term is described in Item 304(a)(1)(iv) of Regulation S-K under the Exchange Act, or a reportable event, as that term is defined in Item 304(a)(1)(v) of Regulation S-K under the Exchange Act.

The Company provided Malone with a copy of the foregoing disclosures prior to the filing of this Report and requested that Malone furnish the Company with a letter addressed to the SEC stating whether it agrees with the statements made by the Company set forth above. A copy of Malone's letter, dated February 16, 2024, is attached as Exhibit 16.1 to this Report.

#### Item 9.01 Financial Statements and Exhibits

##### (d) Exhibits

16.1 [Letter from MaloneBailey LLP to the Securities and Exchange Commission dated February 16, 2024.](#)

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

-2-

---

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Greenwich LifeSciences, Inc.**

Date: February 20, 2024

By: /s/ Snehal Patel

Snehal Patel

Chief Executive Officer

---

-3-

---



February 16, 2024

U.S. Securities and Exchange Commission  
100 F Street, N.E.  
Washington, DC 20549

We have read the statements under Item 4.01 of the Current Report on Form 8-K of Greenwich LifeSciences, Inc. to be filed with the Securities and Exchange Commission on or about February 20, 2024. We agree with all statements pertaining to us. We have no basis on which to agree or disagree with the other statements contained therein.

*Malone Bailey, LLP*

MaloneBailey, LLP  
www.malonebailey.com  
Houston, Texas

10370 Richmond Avenue, Suite 600, Houston, Texas 77042 USA	713 343 4286
Room 1902, Lenovo Houhai Center (Tower A), No. 3288 Houhaibin Road, Nanshan District, Shenzhen 518054, P.R. China	86 755 86278659
Room 707, 7th Floor, SK Tower, No.6A Jianguomenwai Avenue, Chaoyang District, Beijing 100022, P.R. China	86 010 85563995
Level 9, Ariake Frontier Building Tower B, 3-7-26 Ariake Koto-ku, Tokyo 135-0063 Japan	81 3 5530 8447
<a href="http://www.malonebailey.com">www.malonebailey.com</a>	

Public Company Accounting Oversight Board Registered AICPA  
An Independently Owned and Operated Member of Nexia International

